(HealthDay)—For kids ages 12 to 17 years, the effectiveness of beefy vaccination with two doses of the Pfizer-BioNTech vaccine is 92 p.c against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), in conserving with analyze printed in the Dec. 31 place of the U.S. Facilities for Disease Grasp a watch on and Prevention Morbidity and Mortality Weekly Document.
Karen Lutrick, Ph.D., from the College of Arizona in Tucson, and colleagues tested 243 kids ages 12 to 17 years for SARS-CoV-2 by reverse transcription-polymerase chain response per week, no matter symptoms, and on onset of COVID-19-like sickness throughout July 25 to Dec. 4, 2021, in a doable cohort stumble on conducted in Arizona. For the interval of the stumble on, the B.1.617.2 (delta) variant became as soon as the predominant SARS-CoV-2 stress; 190, 30, and 66 kids contributed fully vaccinated person-time, partially vaccinated person-time, and unvaccinated person-time, respectively.
The researchers learned that after adjustment for sociodemographic characteristics, effectively being data, frequency of social contact, veil exhaust, put, and local virus circulation, the estimated vaccine effectiveness of beefy Pfizer-BioNTech vaccination became as soon as 92 p.c for preventing SARS-CoV-2 infection.
“The vaccine effectiveness estimates described on this file for the Pfizer-BioNTech vaccine in exact-world stipulations throughout the interval of delta variant predominance corroborate and amplify upon the vaccine effectiveness estimates from different fresh reports in kids and toughen old findings that fresh vaccination efforts are ensuing in huge preventive advantages amongst kids susceptible 12 to 17 years,” the authors write.
One creator disclosed financial ties to the pharmaceutical alternate; a second creator disclosed ties to the clinical expertise and publishing industries.
More data:
Abstract/Plump Text
Copyright © 2021 HealthDay. All rights reserved.
Citation:
BNT162b2 vaccine effectiveness 92 p.c for children ages 12 to 17 (2021, December 31)
retrieved 3 January 2022
from https://medicalxpress.com/data/2021-12-bnt162b2-vaccine-effectiveness-p.c-kids.html
This doc is self-discipline to copyright. Other than any shapely dealing for the cause of within most stumble on or study, no
section would possibly additionally very effectively be reproduced with out the written permission. The vow material is equipped for data functions entirely.
